Skip To Main Content
D. A. Eichenauer on Muck Rack

D. A. Eichenauer

As seen in: Nature, Annals of Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to D. A. Eichenauer’s profile

Articles by D. A. Eichenauer

|
By P. J. Bröckelmann, B. von Tresckow, D. A. Eichenauer, S. Borchmann, J. Ferdinandus, H. Tharmaseelan, C. Kobe, W. Klapper
| Nature Verified
Correction to: Leukemia https://doi.org/10.1038/s41375-025-02567-w, published online 24 March 2025 In this article the author’s name D. A. Eichenauer. was incorrectly written as D. Eichenauer. The original article has been corrected. Additional information The original article can be found online at https://doi.org/10.1038/s41375-025-02567-w.
Open in Who Shared Issue with article?

Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials | Leukemia

|
By P. J. Bröckelmann, D. A. Eichenauer, S. Borchmann, J. Ferdinandus, W. Klapper, H. Tharmaseelan, C. Kobe
| Nature Verified
To the Editor: Progression-free survival (PFS) and overall survival (OS) are key indicators of treatment success in Hodgkin lymphoma (HL), both in the context of first-line treatment and in relapsed HL. While OS is often prioritized by regulatory authorities and health technology assessment bodies [1], PFS is highly relevant to patients and frequently serves as primary endpoint in clinical research [2].
Open in Who Shared Issue with article?

Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

|
By D. A. Eichenauer, A. Engert, M. André, UCL Namur, M. Federico
| Annals of Oncology Verified
The crude incidence of Hodgkin's lymphoma (HL) in the European Union is 2.3 and the mortality is 0.4 cases/100 000/year. Young adults aged 20–40 years are most often affected; however, a second incidence peak is seen in individuals aged 55 and older. Slightly more men than women are diagnosed with HL. Histologically, classical HL (cHL) accounting for ∼95% of all HL cases is distinguished from nodular lymphocyte-predominant HL (NLPHL) representing ∼5% of all HL cases.
Open in Who Shared Issue with article?
Show More